Vanda Pharmaceuticals Criticizes FDA Draft Guidance on Animal Testing Alternatives
Event summary
- Vanda Pharmaceuticals criticized the FDA's March 18, 2026 draft guidance on New Approach Methodologies (NAMs) for lacking concrete examples and practical pathways to replace animal testing.
- The company highlighted the absence of specific NAMs accepted by the FDA, validated studies, and clear approval criteria.
- Vanda urged the FDA to withdraw and revise the draft with stronger scientific grounding and industry collaboration.
- The CEO emphasized the need for faster, safer drug development and reduced animal suffering, particularly in dogs.
The big picture
Vanda's criticism reflects broader industry tensions between regulatory caution and the push for modern, human-relevant drug development tools. The FDA's guidance is a critical step in shifting away from animal testing, but its lack of specificity risks slowing adoption. The outcome will impact drug development timelines, ethical standards, and investor confidence in biopharmaceutical innovation.
What we're watching
- Regulatory Reform
- Whether the FDA will revise the draft guidance to include concrete examples and expedited pathways for NAMs.
- Industry Collaboration
- The extent to which the FDA engages with industry innovators, scientists, and animal welfare groups during the comment period.
- Scientific Validation
- The pace at which validated NAMs are incorporated into regulatory acceptance criteria.
Related topics